An observational study in Long-term Major Cardiovascular Events, Myocardial Infarction and Percutaneous Coronary Intervention, sponsored by Kiyuk Chang. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-04-20.
Sponsored by Kiyuk Chang · Observational
The purpose of this registry is to evaluate long-term clinical events in patients with acute myocardial infarction who were treated with percutaneous coronary intervention.
Although numerous articles have been published by using nationwide Korean myocardial infarction registries, such as the Korea Acute Myocardial Infarction Registry (KAMIR), limitation of previous registries is that these have little data beyond the first year of MI. Therefore, current registry was designed to assess long-term clinical events in patients with acute myocardial infarction.
Because most of myocardial infarction patients were treated by revascularization in real world of Korea, this registry limits the inclusion criteria to patients who were treated with percutaneous coronary intervention to reduce the bias.
Cardiovascular center with high-volume percutaneous coronary intervention of following hospitals were participated.
Cheonnam University Hospital, Gwangju, South Korea
8 hospitals of the Catholic University of Korea already have web-based coronary intervention registry (NCT01239914). And Cheonnam University Hospital is one of leading hospitals to design and manage the web-based previous Korean nationwide myocardial infarction registry, such as such as the Korea Acute Myocardial Infarction Registry (KAMIR) (http://www.kamir.or.kr/).
All consecutive acute myocardial infarction patients had been enrolled in each registries prospectively.
Using these previous data, current registry update new clinical and angiographic variables and assess long-term clinical follow-up data retrospectively.
2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.
This study's enrollment of 4,748 is above the median of 500 across 983 observational studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →Kiyuk Chang is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Acute myocardial infarction who were treated with percutaneous coronary intervention
Exclusion Criteria:
ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
Device: Percutaneous coronary intervention
Non-ST-segment elevation acute myocardial infarction teated with percutaneous coronary intervention
Device: Percutaneous coronary intervention
Percutaneous coronary intervention
Percutaneous coronary intervention
Major adverse cardiac and cerebrovascular events
Time frame: 5 years
All-cause death
Time frame: 5 years
Cardiac death
Time frame: 5 years
Nonfatal myocardial infarction
Time frame: 5 years
Nonfatal stroke
Time frame: 5 years
Target lesion revascularization
Time frame: 5 years
Target vessel revascularization
Time frame: 5 years
Non-target vessel revascularization
Time frame: 5 years
Definite/Probable stent thrombosis
Time frame: 5 years
Hospitalization for heart failure
Time frame: 5 years
Bleeding defined as the Bleeding Academic Research Consortium (BARC) definitions type 2, 3, and 5
Time frame: 5 years
Bleeding defined as the thrombolysis In Myocardial Infarction (TIMI) major/minor
Time frame: 5 years
No study locations are listed for this record.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kiyuk Chang